News
🌏 Asia-PacificLatest pharmaceutical news, drug approvals, and NMPA regulatory updates
Latest News
Nuance Pharma Secures IND Clearance for Actair® in China
Nuance Pharma has received IND clearance for its pivotal clinical trial of Actair® in China, a significant step in oncology development. This announcement has important implications for investors and business development teams.
Bukwang Pharmaceutical Partners with DreamCIS and AWS for Clinical Trials
Bukwang Pharmaceutical has signed a strategic MOU with DreamCIS and AWS to enhance clinical trial processes. This partnership aims to leverage technology for improved outcomes.
Lundbeck Secures Korean Approval for Vyepti: Implications for Oncology and Migraine Treatment
Lundbeck has received approval for Vyepti in Korea, marking a significant milestone in migraine treatment. This development has important implications for the oncology sector as well.
60 Degrees Pharmaceuticals Initiates Clinical Trial for Tafenoquine in Babesiosis Patients
60 Degrees Pharmaceuticals has announced the early enrollment of its first seasonal patient in a clinical trial for Tafenoquine aimed at treating Babesiosis. This development could have significant implications for the pharmaceutical landscape.
Health News Round-Up: Immunotherapy, PCOS, and Clopidogrel Trials
This article provides a concise overview of recent clinical trials in immunotherapy for depression, the transition from PCOS to PMOS, and clopidogrel's efficacy for East Asian patients.
Clinical Trials Day 2026: Oncology Study Growth Insights
As Clinical Trials Day 2026 approaches, oncology research shows significant growth. This article analyzes the implications for pharmaceutical stakeholders.
Clinical Trials Day 2026: Research Rising in Oncology
On Clinical Trials Day 2026, the oncology sector shows significant study growth, reflecting the 'Research Rising' theme. This article delves into the implications for pharma stakeholders.
Kelun and Merck's Lung Cancer Combo Shows Promise in China
Kelun and Merck's combination therapy for lung cancer has demonstrated improved survival rates in a late-stage trial in China, raising investment interest.
Ildong Pharmaceutical Stock: Earnings and Pipeline Insights
Ildong Pharmaceutical's recent earnings report and pipeline developments have captured investor interest, signaling potential growth opportunities.
ZTE Partners with China's National Clinical Research Center for Clinical Trials
ZTE has announced a strategic partnership with China's National Clinical Research Center for interventional medicine, focusing on clinical trials. This collaboration aims to enhance research capabilities and drive innovation in the pharmaceutical sector.
Novartis Strengthens Prostate Cancer Treatment with Pluvicto
Novartis has reported stronger PSA responses with its drug Pluvicto in earlier-stage prostate cancer, indicating promising developments in oncology. This news could reshape competitive dynamics in the market.
Asia-Pacific Regulatory Updates: TGA Guidance on Compounded Medicines
The TGA has released new guidance impacting the manufacturing and advertising of compounded medicines. This article breaks down the implications for the pharmaceutical industry.
Fierce Pharma Asia: BMS-Hengrui's $15B Deal and More
Bristol Myers Squibb and Hengrui's $15B deal marks a significant shift in oncology investments. Meanwhile, Takeda announces major layoffs affecting 4,500 employees.
Global Pharmacovigilance Reporting: Key Regulatory Updates
This article provides a comparative analysis of adverse event reporting obligations across five major regulatory authorities, highlighting key updates and implications for the pharmaceutical industry.
Asia Bacitracin Ointment Market Analysis and Regulatory Updates
This article provides a comprehensive analysis of the Bacitracin ointment market in Asia, highlighting key trends and regulatory updates that impact investment decisions.
India's CDSCO Adopts Prior Intimation System for Clinical Trials
India's CDSCO has implemented a new prior intimation system to enhance the efficiency of clinical trial startups. This move is expected to significantly influence investment strategies in the region.
The Week in Pharma: Action, Reaction, and Insight – May 15, 2026
This article provides a comprehensive overview of significant oncology developments in the pharmaceutical sector for the week ending May 15, 2026. Gain insights into the implications for business development teams and investors.
Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes
This article covers significant developments in the pharmaceutical sector, including BMS's $15B deal with Hengrui, Takeda's workforce reductions, and Daiichi's oncology initiatives.
PDA Manufacturing APAC: Key Highlights and Takeaways
The PDA Pharmaceutical Manufacturing conference in the Asia-Pacific region highlights critical trends reshaping pharmaceutical production, including digital transformation, continuous manufacturing adoption, and supply chain resilience strategies.
PDA APAC: Manufacturing Innovations Day 1 Roundup
PDA APAC Pharmaceutical Manufacturing Day 1 highlighted manufacturing innovations, regulatory harmonization challenges, and the critical role of advanced technologies in reshaping APAC pharmaceutical production. Expert panels emphasized supply chain resilience, workforce development, and the imperative for manufacturers to adopt continuous manufacturing and quality-by-design principles.